vysnova-saberII-Contract
,

Vysnova Awarded TO-0734 Under NAMRU 2 SABER II IDIQ Contract

 

Vysnova Awarded TO-0734 Under NAMRU 2 SABER II IDIQ Contract

 

September 30, 2018: Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0734 (TO 0734) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0734 Vysnova will develop a Viet Nam malaria country plan. Specifically, TO 0734 will involve conducting interviews with malaria control personnel and agencies within Viet Nam to identify gaps in current programs as well as providing recommendations for training, material and research to address gaps.

Vysnova-awarded-TO0698-NAMRU2-SABER
,

Vysnova Awarded TO 0698 Under NAMRU-2 SABER II

Vysnova-awarded-TO0698-NAMRU2-SABER

Vysnova Awarded TO 0698 Under NAMRU-2 SABER II

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0698 (TO 0698) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0698 Vysnova will provide support to surveillance project designed to determine the spatial and temporal distribution of medically important vectors and reservoir host in the Indo-Pacific Command (INDOPACOM) region. Specifically, this program consists of 3 main research projects across Cambodia.

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract
,

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0740 (TO 0740) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0740 Vysnova will provide support to conduct a surveillance research study for dengue and dengue-like illnesses that present to the Johor Bahru District Health Office’s fever clinic in Malaysia.

Vysnova Partners Inc Awarded TO 0743 Under NAMRU-2 SABER II IDIQ Contract
,

Vysnova Partners Inc Awarded TO 0743 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc Awarded TO 0743 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc Awarded TO 0743 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0743 (TO 0743) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0743 Vysnova will provide support to conduct an environmental surveillance research study for leptospirosis pathogens circulating in river soils and contaminated water sources in Sarawak, Malaysia.

vysnova to 0744 NAMRU2
,

Vysnova Partners Inc. Awarded TO 0744  Under NAMRU- 2 SABER II IDIQ Contract.

vysnova to 0744 NAMRU2

Vysnova Partners Inc. Awarded TO 0744  Under NAMRU- 2 SABER II IDIQ Contract.

 

Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0744 (TO 0744) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract.
Under TO 0744 Vysnova will provide support to conduct a surveillance research study for febrile and respiratory illnesses in northern, central and southern Laos.

vysnova-saberII-Contract
,

Vysnova Awarded TO0745 Under NAMRU-2 SABER II IDIQ Contract

 

Vysnova Awarded TO0745 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018: Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0745 (TO 0745) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Bio-surveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract.

Under TO 0745 Vysnova will provide support for the Defense Malaria Assistance Program. Specifically, TO 0745 will involve developing reports to summarize DMAP activities, establish harmonized malaria research and surveillance protocols, and support periodic advisory panel meetings to inform current and future DMAP.

Project Spotlight: Zika Research in Infants and Pregnant Women in Colombia

The Problem:

Zika Virus (ZIKV) was declared a global health threat in 2016.  Although most of the cases can be attributed to infected bites of Aedes aegypti and Aedes albopictus mosquitoes, a proportion of new Zika infections are due to sexual transmission from infected males to their partnersZIKV infection features general symptoms such as mild headaches and fever.  However, consequences of infections during pregnancy can be catastrophic. ZIKV infections during pregnancy are causally linked to microcephaly in new born babies (small heads) and other negative pregnancy outcomes.

Learn more about Zika from the CDC.

The Work:

The project Zika en Embarazadas y Ninos (ZEN) targets the population who were exposed to ZIKV.  ZEN has been executed in two phases.   During the first phase, the project staff followed a cohort of pregnant women, their partners, and their newborn infants, in the regions of Atlántico, Valle, and Santander in Colombia to better understand the association between ZIKV during pregnancy and the spectrum of possible adverse outcomes related to infection during pregnancy.  During the second phase, the babies from the first phase-cohort are followed to further explore functional deficits, their magnitude, and their association to other deficits later in life.  For this purpose, the Centers of Disease Control and Prevention and the Instituto Nacional de Salud in Colombia proposed the recruitment and follow-up of 5000 women and their 1250 children, until children reach 4 years of age.

The Vysnova Impact:

Vysnova provides comprehensive project management support for the scientific research of the ZEN study. We help our client meet their objectives by managing international purchases, human resources, technical requirements, and logistics, all while controlling costs and providing risk management.

Through crucial partnerships and subcontractors, Vysnova ensures high quality research and procures the technical skills needed for the study. We partner with academic institutions conducting similar research in Latin America to increase the study’s sample size of women who have or have been exposed to ZIKV. Vysnova also works closely with local companies to provide digital data storage and management for the samples collected from the field. This allows our client to easily analyze and access the data, which will be utilized for years to come. Vysnova also recruits and hires technical experts in child psychology that train field staff to assess babies with specific tools. These assessments analyze motor skills, psychological capacity, and other developmental patterns found within the children being studied. These skills are easily transferable to other ZIKV studies and enhance specialization of Colombian medical staff that will be used long after the study concludes.

The success of our clients’ projects is at the forefront of our efforts here at Vysnova. Our greatest contribution to that success lies in the relationships that Vysnova fosters through partnerships, subcontractors, local staff, vendors, and consultants. Vysnova looks forward to continuing to support public health projects within Latin America and globally.

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract
, ,

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0738 (TO 0738) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0738 Vysnova will provide an in-depth analysis for a clinical study evaluating the role of the candidate predictive biomarker, tryptase, for dengue fever security.